Accessibility Menu
Protagonist Therapeutics Stock Quote

Protagonist Therapeutics (NASDAQ: PTGX)

$74.99
(-2.3%)
-1.73
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$75
Daily Change
(-2.3%) $1.73
Day's Range
$74.78 - $77.22
Previous Close
$75
Open
$76.51
Beta
1.35
Volume
929,935
Average Volume
1,083,110
Market Cap
4.8B
Market Cap / Employee
$76.72M
52wk Range
$33.31 - $93.25
Revenue
-
Gross Margin
0.99%
Dividend Yield
N/A
EPS
$0.71
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Protagonist Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
PTGX+63.34%+293.84%+31.54%+556%
S&P+14.84%+96.04%+14.41%+208%

Protagonist Therapeutics Company Info

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$5.55M33.1%
Gross Profit$5.24M60.1%
Gross Margin94.52%15.9%
Market Cap$3.43B68.6%
Market Cap / Employee$26.35M45.2%
Employees1304.0%
Net Income-$34.77M-13.6%
EBITDA-$41.74M-10.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$168.54M-52.6%
Accounts Receivable$23.36M54232.6%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$9.11M-17.0%
Short Term Debt$2.17M0.0%

Ratios

Q2 2025YOY Change
Return On Assets7.81%-28.5%
Return On Invested Capital-21.34%24.2%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$29.59M-111.0%
Operating Free Cash Flow-$28.78M-110.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Earnings16.889.1863.5777.56488.03%
Price to Book4.884.324.374.9737.10%
Price to Sales8.585.9014.6516.78152.10%
Price to Tangible Book Value4.884.324.374.9737.10%
Price to Free Cash Flow TTM12.1314.029.0894.62928.25%
Enterprise Value to EBITDA-56.9016.92-130.14-70.7170.56%
Free Cash Flow Yield8.2%7.1%11.0%1.1%-90.27%
Return on Equity41.0%54.4%9.0%8.6%-78.85%
Total Debt$10.90M$10.87M$11.36M$11.28M2.81%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.